CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.06.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Lan Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA. Electronic address: lan_zhao@rush.edu. Hauptthemen laut MEDLINE: SOX9 Transcription Factor, Osteoarthritis, Mesenchymal Stem Cells, Transcription Factor RelA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Osteoarthritis (OA) is a painful and debilitating disease affecting over 500 million people worldwide. Intraarticular injection of mesenchymal stromal cells (MSCs) shows promise for the clinical treatment of OA, but the lack of consistency in MSC preparation and application makes it difficult to further optimize MSC therapy and to properly evaluate the clinical outcomes. In this study, we used Sox9 activation and RelA inhibition, both mediated by the CRISPR-dCas9 technology simultaneously, to engineer MSCs with enhanced chondrogenic potential and downregulated inflammatory responses. We found that both Sox9 and RelA could be fine-tuned to the desired levels, which enhances the chondrogenic and immunomodulatory potentials of the cells. Intraarticular injection of modified cells significantly attenuated cartilage degradation and palliated OA pain compared with the injection of cell culture medium or unmodified cells. Mechanistically, the modified cells promoted the expression of factors beneficial to cartilage integrity, inhibited the production of catabolic enzymes in osteoarthritic joints, and suppressed immune cells. Interestingly, a substantial number of modified cells could survive in the cartilaginous tissues including articular cartilage and meniscus. Together, our results suggest that CRISPR-dCas9-based gene regulation is useful for optimizing MSC therapy for OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA. Electronic address: lan_zhao@rush.edu.
- Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA.
- Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA. Electronic address: jian_huang@rush.edu.
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Zhao, L., Lai, Y., Jiao, H., Li, J., Lu, K., & Huang, J. (2024). CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.06.016
Vancouver
Zhao L, Lai Y, Jiao H, Li J, Lu K, Huang J. CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.06.016
BibTeX
@article{Zhao2024,
author = {Zhao, Lan and Lai, Yumei and Jiao, Hongli and Li, Jun and Lu, Ke and Huang, Jian},
title = {CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.06.016}
}
EUVIMED